Loading briefing details...
Loading briefing details...
News Abstract
By: PointLine Media Research & Editorial Team
Topic:Business,Health,Industry,Science & Environment,Technology
September 24, 2026
Creative Biolabs has updated its catalog of research-grade antibodies to include more options for studying HIV-1, HIV-2, and HTLV-1. These reagents target specific viral proteins to assist laboratory investigations into how these viruses function and interact with host immune systems.
The expansion features tools designed to isolate key viral markers, such as the gp140 protein in HIV-1 and the gp36 antigen in HIV-2. By providing these specific markers, the company aims to support researchers working on viral entry mechanics and the development of new diagnostic assays.
Additionally, the firm is offering reagents for HTLV-1, specifically targeting the gag p19 protein. These antibodies are intended for use in common laboratory procedures like ELISA and Western blotting to help scientists analyze viral protein expression and disease pathogenesis.
The global scientific community continues to focus heavily on the mechanisms of human retroviruses, which remain significant public health concerns. As researchers work to better understand viral lifecycles and immune evasion, the demand for precise biological reagents has steadily increased.
By expanding the availability of specialized antibodies, suppliers are facilitating more granular analysis of viral proteins. This trend reflects a broader push toward standardized, high-quality research tools that allow for better reproducibility and accuracy in infectious disease studies.